ICC Expanding to New Zealand with NUBU Supply Agreement
July 25th, 2019
App, Exclusive, News, Top News
Although the possession of any amount of cannabis has been illegal in New Zealand since 1975, half of the population aged 17-65 admit to trying cannabis, while one in six report being regular users, giving the country the ninth-highest cannabis consumption level in the world.
In December of last year, the Misuse of Drugs act was amended to allow terminally-ill patients access to medicinal cannabis, and as part of the 2020 general election, New Zealand will hold a binding yes/no referendum question on the legalization of cannabis for personal use. Polling shows strong support for the legalization of cannabis for medical purposes, and slightly lower but growing support for recreational legalization, and the liberalization of cannabis regulations is expected to enable cultivation and the creation of a national cannabis industry.
In keeping with its solid record of expanding early into emerging markets, International Cannabis Corporation (CSE: WRLD, FWB: 8K51, OTC: WLDCF) has entered into an exclusive supply and commercial rights agreement with NUBU Pharmaceuticals, a licensed New Zealand medical cannabis company.
Founded in 2017, NUBU Pharmaceuticals is widely considered a first mover within New Zealand’s high-value medical cannabis industry, and in partnership with ICC, NUBU is now equipped with best-in-class product formulations and supply chain infrastructure to deliver reputable and clinically-effective medicinal cannabis products to New Zealand. NUBU was awarded a license to deal in controlled drugs by New Zealand’s Ministry of Health earlier this year as well as a license to sell medicines wholesale, allowing it to import and distribute ICC-manufactured THC/CBD products ahead of its competitors.
ICC is committed to servicing all links of the cannabis value chain, including the manufacture and export of finished products to developing international marketplaces, and plans to leverage its existing brand portfolio, European GMP-certified processing facilities, and extraction-ready inventories to service New Zealand’s patient population while maximizing margins and profitability.
Under the terms of the agreement, ICC will supply a suite of full-spectrum, pharmaceutical-grade medical cannabis products including oil/tincture and capsules in finished-goods form, ICC-branded, co-branded, and/or ICC-labeled medical cannabis products currently under development including, but not limited to oil, capsules, transdermal patches, oral sprays, inhalers, and vape cartridges. It will also provide hemp-derived CBD adhering to the international standard of less than 0.3% THC in both bulk form (isolate, distillate, full spectrum oil) and finished good forms.
Commenting on the agreement, David Shpilt, Chief Executive Officer of International Cannabis said, “ICC’s exclusive supply and commercial rights agreement with NUBU successfully catapults the company into yet another high-value medical cannabis jurisdiction. The marriage of International Cannabis’ superior product formulation capabilities and extensive CPG/branded product market entrance experience, coupled with NUBU’s unique CBD/THC distribution infrastructure, will permit continued brand loyalty while addressing priority medical conditions within the Asia-Pac theatre.”
New Zealand’s population is quickly approaching five million, but NUBU isn’t interested in servicing the country’s population alone, and is already looking outside for even greater opportunities. Noting New Zealand’s long history of robust agricultural exports, NUBU believes that exporting cannabis and derivatives to meet the world’s growing demand is a natural fit, and ICC plans to be an integral part of its future plans.
Shpilt added, “In collaboration with NUBU, the company is also in discussions about the distribution of a number premium value-add medicinal and wellness products from New Zealand to export markets internationally. ICC now boasts supply, distribution and commercial rights agreements with a host of high-profile cannabis operators across a variety of territories primed for exponential growth such as India, Germany, New Zealand, and Colombia.”
With an established presence on five continents, 110 clients representing roughly 3500 pharmacies in 16 countries, five licenses for cultivation on three continents, and access to over 850 acres of premium hemp crops estimated to produce up to 6800 tons of biomass for CBD extraction, International Cannabis certainly lives up to its name, and the NUBU agreement furthers its ultimate goal of creating the first truly global cannabis supply chain.
For more of the ICC story, keep watching this page, or visit https://intlcannabiscorp.com/
And connect with them on social media:
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.